AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26721823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination introduced in 2006
Number of subjects: 40552
Study 26721823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 40552
Study 26722126 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycine levels
Number of subjects: 4109
Study 26722126 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycine levels in patients with apolipoprotein B, low-density lipoprotein cholesterol, or apolipoprotein A-1 above the median
Number of subjects: 4109
Study 26723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 6
Study 26723501 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400mg bid capsule monotherapy
Number of subjects: 193
Study 26724322 — intervention group
Group type: EXPERIMENTAL
Intervention: B Cell Depletion Therapy
Number of subjects: 0
Study 26725208 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide risk screening
Number of subjects: 200
Study 26725208 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of patient opinions
Number of subjects: 200
Study 26725209 — intervention group
Group type: EXPERIMENTAL
Intervention: TB < 2.0 mg/dL
Number of subjects: 137
Study 26725209 — intervention group
Group type: COMPARATOR
Intervention: TB ≥ 2.0 mg/dL
Number of subjects: 137
Study 26725459 — intervention group
Group type: COMPARATOR
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 355
Study 26725459 — intervention group
Group type: COMPARATOR
Intervention: Functional Status II (Revised)
Number of subjects: 355
Study 26725459 — intervention group
Group type: EXPERIMENTAL
Intervention: CHQ and Functional Status II
Number of subjects: 355
Study 26725920 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Number of subjects: 379
Study 26726900 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group with appropriate cuff sizes based on arm circumferences
Number of subjects: 104
Study 26726900 — intervention group
Group type: COMPARATOR
Intervention: Control group with appropriate cuff sizes based on arm circumferences
Number of subjects: 104
Study 26728744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 299
Study 26728744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide
Number of subjects: 299
Study 26728744 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index)
Number of subjects: 299
Study 26729345 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/Bendamustine (RB) followed by Rituximab/High-dose Cytarabine (RC)
Number of subjects: 23
Study 26729395 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and health assessments for high-risk CVD subjects including ECG, ultrasound scan, blood and urine analysis, and lifestyle questionnaire.
Number of subjects: 400000
Study 26729395 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments including blood pressure, weight, ECG, and questionnaires on survival status, hospitalisations, and lifestyle.
Number of subjects: 400000
Study 26729395 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary analysis of the first 0.1 million participants screened.
Number of subjects: 400000
Study 26729445 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 1754
Study 26729445 — intervention group
Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 1754
Study 26729445 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 1754
Study 26729653 — intervention group
Group type: EXPERIMENTAL
Intervention: Various immunosuppressants
Number of subjects: 0
Study 26729653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to alloantigen from allografts
Number of subjects: 0
Study 26729855 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 60
Study 26729855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 60
Study 26729855 — intervention group
Group type: COMPARATOR
Intervention: NIRS in pre-existing stents
Number of subjects: 60
Study 26731175 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV/FTC with EFV
Number of subjects: 79
Study 26731755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical cidofovir cream applied intraanally three times per week for 4 weeks
Number of subjects: 17
Study 26731755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical cidofovir cream
Number of subjects: 17
Study 26732570 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional pseudocontinuous arterial spin labeling with postlabeling delays of 1.5 s and 2.5 s
Number of subjects: 41
Study 26732570 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional pseudocontinuous arterial spin labeling
Number of subjects: 41
Study 26733541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (nHF)
Number of subjects: 28
Study 26733671 — intervention group
Group type: EXPERIMENTAL
Intervention: QUAD therapy with daclatasvir (DCV), asunaprevir (ASV), PegIFN, and RBV
Number of subjects: 22
Study 26733671 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV/ASV regimen
Number of subjects: 22
Study 26733671 — intervention group
Group type: COMPARATOR
Intervention: PegIFN/RBV therapy
Number of subjects: 22
Study 26734580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (20 mg/m(2) on days 1 and 8) and 5-FU (330 mg/m(2) continuously on days 1-5 and 8-12) via an implanted catheter system.
Number of subjects: 18
Study 26735686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 10
Study 26735686 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 10
Study 26735992 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (200 to 250 ml transfusions, 2 consecutive transfusions)
Number of subjects: 99
Study 26735992 — intervention group
Group type: COMPARATOR
Intervention: Control group (418 patients treated during the previous 5 months)
Number of subjects: 99
Study 26735992 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 99
Study 26736064 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing analysis in families with severe COPD
Number of subjects: 347
Study 26736064 — intervention group
Group type: COMPARATOR
Intervention: Exome sequencing analysis in cases with severe COPD
Number of subjects: 347
Study 26736871 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate and multivariate analyses to predict mortality in the following 7 days
Number of subjects: 23
Study 26738624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical decompressive surgery
Number of subjects: 50
Study 26738669 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 reaction units (PRU) quintile 5 (most inhibited)
Number of subjects: 8582
Study 26738669 — intervention group
Group type: COMPARATOR
Intervention: P2Y12 reaction units (PRU) quintile 1 (least inhibited)
Number of subjects: 8582
Study 26738949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restricted (<2,500 mg/d)
Number of subjects: 902
Study 26738949 — intervention group
Group type: COMPARATOR
Intervention: Sodium unrestricted (≥2,500 mg/d)
Number of subjects: 902
Study 26738949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restricted (<2,500 mg/d) in patients not receiving ACE inhibitors or ARBs
Number of subjects: 902
Study 26739033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast followed by a standardized meal
Number of subjects: 42
Study 26739478 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified endaural approach
Number of subjects: 75
Study 26739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT) infection
Number of subjects: 718
Study 26739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae (NG) infection
Number of subjects: 718
Study 26739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 718
Study 26739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and counselling
Number of subjects: 924
Study 26739730 — intervention group
Group type: COMPARATOR
Intervention: Counselling only
Number of subjects: 924
Study 26739732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily for 21 days preoperatively
Number of subjects: 35
Study 26740638 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet
Number of subjects: 0
Study 26740893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day desloratadine for 4 weeks
Number of subjects: 85
Study 26740893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day levocetirizine for 4 weeks
Number of subjects: 85
Study 26740893 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 85
Study 26740893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both H1 antihistamines
Number of subjects: 85
Study 26740893 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine and desloratadine
Number of subjects: 85
Study 26740893 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust sensitization
Number of subjects: 85
Study 26740901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) with b factor of 1000 s/mm(2)
Number of subjects: 48
Study 26740901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI)
Number of subjects: 48
Study 26740901 — intervention group
Group type: COMPARATOR
Intervention: T2 weighted images
Number of subjects: 48
Study 26741046 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 26741046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 0
Study 26741046 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke (CS) exposure
Number of subjects: 0
Study 26741949 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding systems (using mother's own milk, donor milk, and preterm formula)
Number of subjects: 26
Study 26742009 — intervention group
Group type: COMPARATOR
Intervention: Statin use (any statin at baseline)
Number of subjects: 118357
Study 26742009 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 118357
Study 26742009 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 118357
Study 26742009 — intervention group
Group type: COMPARATOR
Intervention: Lipophilic statins
Number of subjects: 118357
Study 26742009 — intervention group
Group type: COMPARATOR
Intervention: Low and high potency statins
Number of subjects: 118357
Study 26743093 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir
Number of subjects: 874
Study 26743093 — intervention group
Group type: EXPERIMENTAL
Intervention: PHOTON-1
Number of subjects: 874
Study 26743093 — intervention group
Group type: EXPERIMENTAL
Intervention: TURQUOISE-I
Number of subjects: 874
Study 26743093 — intervention group
Group type: EXPERIMENTAL
Intervention: ION-4
Number of subjects: 874
Study 26743093 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLY-2
Number of subjects: 874
Study 26743463 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomographic assessment of coronary calcification in patients with ST-segment-elevation myocardial infarction
Number of subjects: 108
Study 26743463 — intervention group
Group type: COMPARATOR
Intervention: Optical coherence tomographic assessment of coronary calcification in patients with stable angina pectoris
Number of subjects: 108
Study 26744120 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 90
Study 26744120 — intervention group
Group type: COMPARATOR
Intervention: TD group
Number of subjects: 90
Study 26745007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 19
Study 26745476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thalamic stimulation for a minimum of 18 months and a maximum of 48 months.
Number of subjects: 40
Study 26745476 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 40
Study 26745506 — intervention group
Group type: EXPERIMENTAL
Intervention: Admixture-adjusted, genotype-guided warfarin dosing algorithm
Number of subjects: 255
Study 26745506 — intervention group
Group type: COMPARATOR
Intervention: Clinical algorithm excluding genotypes and admixture
Number of subjects: 255
Study 26745506 — intervention group
Group type: EXPERIMENTAL
Intervention: Admixture-driven pharmacogenetic algorithm (external validation)
Number of subjects: 255
Study 26745574 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental matrix-derived mesenchymal stem cells (PM-MSCs) injection
Number of subjects: 8
Study 26745574 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 26745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions about the self and self-blame
Number of subjects: 150
Study 26745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid depressive symptoms
Number of subjects: 150
Study 26745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions
Number of subjects: 150
Study 26745686 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential pathway from posttraumatic cognitions to PTSD
Number of subjects: 150
Study 26745856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 parts per million ozone for 2 hours during 15-minute on-off exercise
Number of subjects: 24
Study 26745856 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 24
Study 26746120 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral micro-testicular sperm extraction
Number of subjects: 15
Study 26746120 — intervention group
Group type: COMPARATOR
Intervention: None (control group with no sperm in ejaculates)
Number of subjects: 15
Study 26746120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Number of subjects: 15
Study 26746120 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrotal and renal ultrasound imaging
Number of subjects: 15
Study 26746629 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-expression profiling (GEP) test (AlloMap®)
Number of subjects: 399
Study 26746910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - active motion
Number of subjects: 359
Study 26746910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - hip stability
Number of subjects: 359
Study 26746910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - motor control
Number of subjects: 359
Study 26746910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (PPTs) - flexibility and power
Number of subjects: 359
Study 26746910 — intervention group
Group type: COMPARATOR
Intervention: Known risk factors (age, BMI, gender, excessive flexibility, past injury)
Number of subjects: 359
Study 26747086 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline doses of 250 mg/m2 or more
Number of subjects: 1853
Study 26747086 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart radiation exposure
Number of subjects: 1853
Study 26747086 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure greater than 1500 cGy with any anthracycline exposure
Number of subjects: 1853
Study 26747086 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cardiovascular screening
Number of subjects: 1853
Study 26747132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) for uncomplicated malaria
Number of subjects: 0
Study 26748219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty (ESG)
Number of subjects: 25
Study 26748221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) for 6 weeks
Number of subjects: 41
Study 26748221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) continued long-term
Number of subjects: 41
Study 26748954 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum hsCRP quartiles
Number of subjects: 192
Study 26748954 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline hsCRP
Number of subjects: 192
Study 26748954 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hsCRP
Number of subjects: 192
Study 26748972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine reimbursement
Number of subjects: 4903
Study 26749066 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for RARS
Number of subjects: 40
Study 26749066 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for CRSsNP
Number of subjects: 40
Study 26749226 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ/interleukin-17-producing cells in peripheral blood and skin during acute cellular rejection
Number of subjects: 6
Study 26749226 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum monocyte chemotactic protein-1 level
Number of subjects: 6
Study 26749226 — intervention group
Group type: EXPERIMENTAL
Intervention: T follicular helper cells
Number of subjects: 6
Study 26751375 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely vaccinated
Number of subjects: 1583042
Study 26751375 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompletely vaccinated
Number of subjects: 1583042
Study 26751375 — intervention group
Group type: COMPARATOR
Intervention: Contemporarily unvaccinated
Number of subjects: 1583042
Study 26751375 — intervention group
Group type: COMPARATOR
Intervention: Historically unvaccinated
Number of subjects: 1583042
Study 26751506 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (decreasing BMI)
Number of subjects: 1673
Study 26751506 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (increasing BMI)
Number of subjects: 1673
Study 26751506 — intervention group
Group type: COMPARATOR
Intervention: Weight stability (stable BMI)
Number of subjects: 1673
Study 26751506 — intervention group
Group type: COMPARATOR
Intervention: Survival analysis among BMI trajectory groups
Number of subjects: 1673
Study 26751952 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training on a stationary bike for 30 minutes, three times weekly, for 10 weeks at 70% of VO2max.
Number of subjects: 16
Study 26751952 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (n = 7).
Number of subjects: 16
Study 26752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling dose of Salmeterol and Fluticasone Propionate for 10 days
Number of subjects: 37
Study 26752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic for 5 days (for purulent exacerbations)
Number of subjects: 37
Study 26752061 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-1246 quantified by real-time PCR
Number of subjects: 0
Study 26752061 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology
Number of subjects: 0
Study 26752222 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary extracorporeal perfusion of flaps maintained for 10-13 days
Number of subjects: 3
Study 26752222 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic transfusion of packed red cells
Number of subjects: 3
Study 26753096 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol (SaC) levels in high STC group on Day 1: 2.3 (0.2-9.0) μg/dL; Day 7: 1.1 (0.8-4.6) μg/dL
Number of subjects: 30
Study 26753096 — intervention group
Group type: COMPARATOR
Intervention: Salivary cortisol (SaC) levels in control group: Baseline: 0.4 (0.1-1.4) μg/dL; Peak: 1.1 (0.4-2.5) μg/dL
Number of subjects: 30
Study 26753096 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated free cortisol (cFC) levels in high STC group on Day 1: 0.3 (0.1-0.3) μg/dL; Day 7: 0.2 (0.1-0.3) μg/dL
Number of subjects: 30
Study 26753096 — intervention group
Group type: COMPARATOR
Intervention: Calculated free cortisol (cFC) levels in control group: Baseline: 1.7 (0.4-1.9) μg/dL; Peak: 1.8 (1.0-6.6) μg/dL
Number of subjects: 30
Study 26753096 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cortisol (STC) levels
Number of subjects: 30
Study 26753774 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir + PegIFNα-2a + RBV
Number of subjects: 12
Study 26753774 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα-2a + RBV
Number of subjects: 12
Study 26754175 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative insights from GPs and community members regarding antibiotic prescribing and consumption for UTI.
Number of subjects: 57
Study 26754175 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research methodology.
Number of subjects: 57
Study 26754175 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention informed by social marketing.
Number of subjects: 57
Study 26755520 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) administered intravenously every 3 weeks
Number of subjects: 70
Study 26755709 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (stepwise dosing: 9-28-112 μg/d with weekly dose increases)
Number of subjects: 25
Study 26755709 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (flat dosing: 112 μg/d)
Number of subjects: 25
Study 26755709 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (stepwise dosing)
Number of subjects: 25
Study 26755710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with rIX-FP 40 IU/kg weekly
Number of subjects: 63
Study 26755710 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with rIX-FP 75 IU/kg every 2 weeks
Number of subjects: 63
Study 26755710 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment for bleeding episodes
Number of subjects: 63
Study 26755711 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD plasma cells
Number of subjects: 40
Study 26755712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (90 mg/m(2))
Number of subjects: 0
Study 26755712 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (45 mg/m(2))
Number of subjects: 0
Study 26756117 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 0
Study 26756117 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 0